Suppr超能文献

负载于pH响应性介孔二氧化硅纳米颗粒中的木香烃内酯,以提高稳定性并增强抗纤维化作用。

Costunolide Loaded in pH-Responsive Mesoporous Silica Nanoparticles for Increased Stability and an Enhanced Anti-Fibrotic Effect.

作者信息

Niu Xia, Wang Xiaomei, Niu Bingyu, Meng Yanan, He Hongwei, Wang Yucheng, Li Guiling

机构信息

Institute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100050, China.

出版信息

Pharmaceuticals (Basel). 2021 Sep 23;14(10):951. doi: 10.3390/ph14100951.

Abstract

Liver fibrosis remains a significant public health problem. However, few drugs have yet been validated. Costunolide (COS), as a monomeric component of the traditional Chinese medicinal herb , has shown excellent anti-fibrotic efficacy. However, COS displays very poor aqueous solubility and poor stability in gastric juice, which greatly limits its application via an oral administration. To increase the stability, improve the dissolution rate and enhance the anti-liver fibrosis of COS, pH-responsive mesoporous silica nanoparticles (MSNs) were selected as a drug carrier. Methacrylic acid copolymer (MAC) as a pH-sensitive material was used to coat the surface of MSNs. The drug release behavior and anti-liver fibrosis effects of MSNs-COS-MAC were evaluated. The results showed that MSNs-COS-MAC prevented a release in the gastric fluid and enhanced the dissolution rate of COS in the intestinal juice. At half the dose of COS, MSNs-COS-MAC still effectively ameliorated parenchymal necrosis, bile duct proliferation and excessive collagen. MSNs-COS-MAC significantly repressed hepatic fibrogenesis by decreasing the expression of hepatic fibrogenic markers in LX-2 cells and liver tissue. These results suggest that MSNs-COS-MAC shows great promise for anti-liver fibrosis treatment.

摘要

肝纤维化仍然是一个重大的公共卫生问题。然而,目前仅有少数药物得到验证。莪术醇(COS)作为一种传统中草药的单体成分,已显示出优异的抗纤维化功效。然而,COS的水溶性很差,在胃液中稳定性也不佳,这极大地限制了其口服应用。为提高COS的稳定性、改善其溶解速率并增强其抗肝纤维化作用,选择了pH响应性介孔二氧化硅纳米颗粒(MSNs)作为药物载体。用甲基丙烯酸共聚物(MAC)作为pH敏感材料包覆MSNs表面。对MSNs-COS-MAC的药物释放行为和抗肝纤维化作用进行了评估。结果表明,MSNs-COS-MAC在胃液中阻止释放,并提高了COS在肠液中的溶解速率。在COS剂量减半的情况下,MSNs-COS-MAC仍能有效改善实质坏死、胆管增生和过度胶原沉积。MSNs-COS-MAC通过降低LX-2细胞和肝组织中肝纤维化标志物的表达,显著抑制肝纤维化的发生。这些结果表明,MSNs-COS-MAC在抗肝纤维化治疗方面具有很大的前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68d7/8539632/44719129d6fa/pharmaceuticals-14-00951-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验